Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Featured trial
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

  • 368 views
  • 08 Nov, 2020
  • 1 location
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

-based irreversible inhibitor of the 20S proteasome. This second-generation proteasome inhibitor (PI) is structurally and mechanistically different to the dipeptide boronic acid PI, bortezomib. Compared

  • 58 views
  • 21 Jan, 2021
  • 3 locations
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor

serum pregnancy test
growth factor
dexamethasone
neutrophil count
proteasome inhibitor
  • 22 views
  • 05 Mar, 2022
  • 15 locations
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR

and desensitization protocols, and mainly consisted of steroids, plasma exchange (PE), IVIG and RTX in various modalities. More recently, bortezomib was also proposed.To evaluate the role of a

  • 0 views
  • 24 Mar, 2022
  • 1 location
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 16 Feb, 2022
  • 1 location
Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or

  • 0 views
  • 22 Mar, 2022
  • 1 location
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

to investigate the efficacy and safety of co-administration of daratumumab with bortezomib and dexamethasone (BD) regimen in treatment-nave patients with Mayo 04 stage III AL amyloidosis. We planned

  • 0 views
  • 14 Jun, 2021
  • 1 location
A Study of Evaluating the Safety and Efficacy of ATG-010 Bortezomib and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or

  • 0 views
  • 06 Oct, 2021
  • 28 locations
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.

  • 1 views
  • 09 Feb, 2022
  • 1 location